TechSeeker Profile

Seattle Genetics Inc
Profile last edited on: 8/21/2013

Antibody-drug conjugates (ADCs)
TS Type
Small Corp
Not Small
Year Founded
Last Involved Year

Key People / Management

Location Information

21823 30th Drive Southeast
Bothell, WA 98021
   (425) 527-4000

Public Profile

Only briefly SBIR-involved in the few years after the firm was founded but with some of the current principals having been with the start-up, Seattle Genetics is a now clinical-stage biotechnology company focused on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. the firm's lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. Other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Publicly Traded
Stock Info
Received SBIR $$

Techseeker firm in the news

There are no news available.